GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorGenfleet Therapeutics (Shanghai) Inc.

About this trial

This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Willing to participate in the study and provide written informed consent

Age ≥18 years at the time of signing informed consent; no sex restriction

Histologically or cytologically confirmed colorectal cancer (CRC)

KRAS G12D mutation confirmed by the central laboratory

Disqualifiers

Other malignancy that has progressed or required treatment within 3 years prior to randomization

Known presence of other actionable/targetable driver gene alterations

Leptomeningeal metastases, spinal cord compression, or active/symptomatic brain metastases

Pleural effusion, ascites, or pericardial effusion requiring repeated puncture/drainage (≥2 times/month) or causing significant symptoms within 28 days prior to randomization

Trial design

Design model

Parallel

Treatments tested in this trial

  • GFH375 + Cetuximab

    Drug

    GFH375:600 mg orally, once daily Cetuximab :500 mg/m² intravenously every 2 weeks

  • Fruquintinib

    Drug

    35 mg/m² orally twice daily (max single dose 80 mg) on Days 1-5 and Days 8-12

  • Trifluridine and Tipiracil

    Drug

    5 mg orally once daily on Days 1-21

Treatment groups

368 Participants
are divided into 2 treatment groups
Group A: GFH375 + CetuximabExperimental treatment 1 intervention
Group B: The investigator's choice of treatmentActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Progression-free survival (PFS)

Progression-free survival (PFS) assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Time frame
Up to approximately 2 years
2

Overall survival(OS)

Overall survival

Time frame
Up to approximately three and a half years

Secondary outcomes

1

Progression-free survival (PFS) assessed by the investigator

PFS assessed by the investigator according to RECIST v1.1

Time frame
Up to approximately 2 years
2

Objective response rate (ORR)

Objective response rate (ORR) assessed by BICR and the investigator according to RECIST v1.1

Time frame
Up to approximately three and a half years
3

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v6.0

Time frame
Up to approximately three and a half years
4

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) leading to treatment modifications

Incidence and severity of AEs/SAEs leading to treatment discontinuation, treatment interruption, and dose reduction

Time frame
Up to approximately three and a half years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: